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S256 Poster Session Itransplantation (OHT) followed by autologous hematopoietic stem
cell transplantation (ASCT).
Age at AL presentation was 63, 62 and 44 years in 2 females and 1
male. Diagnosis of cardiac AL was established via endomyocardial
biopsy, Congo red staining and immunohistochemistry. All had
end stage heart failure with New York Heart Association class 4
symptoms and developed cardiogenic shock requiring intra-aortic
balloon pump support as a bridge to OHT. All were considered un-
suitable for ASCT.
ASCT was performed 13, 16 and 13 months after OHT (table-1).
All 3 patients were on tacrolimus and prednisone at the time of stem
cell mobilization and hematopoietic transplant; two patients were
also receiving mycophenolate mofetil and valganciclovir. We col-
lected 6.1 and 6.2 x 106/kg CD-34+ cells in 2 days with filgrastim
(5 ug/kg, twice, daily) and plerixafor (16 mg/kg based on day- 4
CD-34+ counts) in two subjects. The third initially failed to mobilize
but 4.3x106/kg CD-34+ cells were subsequently obtained when she
(patient #2) was remobilized with filgrastim and plerixafor 4 weeks
after stopping mycophenolate mofetil. The creatinine clearance at
the time of high-dose chemotherapy was 36, 30 and 43 ml/minute.
All 3 patients received renal adjusted dose of melphalan at 140mg/
m2.Mycophenolatemofetil andValganciclovir were withheld during
neutropenia until engraftment. Time to engraftment for neutrophils
(ANC of.500/uL x3 days) was 13, 11 and 14 days. Platelets engraft-
ment (untransfused.20 x 109 for 3 consecutive days) occurred in 14,
13 and 16 days. No patients received post-transplant filgrastim. Pa-
tients were hospitalized for 17, 18 and 18 days. Renal function re-
mained stable during ASCT and non-hematological toxicity was
limited to grade I-II apart from one grade III oral mucositis and co-
litis. One patient achieved hematologic complete remission (pa-
tient#2) while 2 patients had partial response following ASCT.
Post OHT and ASCT all patients are alive and well at follow-up
of 14, 26 and 30 months from OHT.
OHT should be considered in select patients with dominant car-
diac involvement and advanced heart failure to allow subsequent
ASCT and improve survival.
Table. Orthotopic heart transplantation (OHT) followed by
ASCT
Time toAge/
SexTime to
AL diagnosis
(months)Organ
involvementInitial
treatmentTime to
OHT*
(months)ASCT
post OHT
(monthsSurvival
(months)63/F 12 Heart,
kidney,
PNLenalidomide/
dexamethasone7 13 32+62/F 24 Heart,
Kidney,
PNMelphalan/
dexamethasone5 16 26+44/M 12 Heart,
Kidney,
tongueLenalidomide/
dexamethasone4 13 16+*Time to OHT from onset of heart failure symptoms, PN 5 peripheral
nerve, F 5 female, M 5 male140
AUTOLOGOUS STEM CELL TRANSPLANT FOR A PATIENT WITH RELAPS-
ING-REMITTING MULTIPLE SCLEROSIS
Ibrahim, K.A. St Vincent’s Hospital, Sydney, NSW, Australia
Objective: To highlight the use of autologous bone marrow trans-
plantation (BMT) as an option for patients with relapsing-remitting
Multiple Sclerosis.
Clinical Features: A 43-year-old female was diagnosed with Multi-
ple Sclerosis (MS) in 2002. She presented with progressive leg weak-
ness resulting in some impairment of mobility and urinary retention
requiring self-catheterisation. She was commenced on glatiramer ac-
etate with little response. In July 2003 her therapy was changed to in-
terferon from which she had profound side effects. She was switched
back to glatiramer but experienced 3-4 relapses per year. Whilst onglatiramer she became pregnant in 2006. Her MS control was very
good during pregnancy. Nine months after delivery her disease re-
lapsed with further worsening of the right leg weakness and blurring
of the vision in the right eye. In 2009 she underwent treatment with
natalizumab once a month. Initially she had some response to nata-
lizumab but after a year of therapy her disease continued to progress
both clinically and radiologically.
Interventions, Case Progress and Outcome: She was then re-
ferred to the BMT unit for considering autologous stem cell trans-
plant (ASCT) for her condition. In December 2010 she underwent
ASCT with conditioning chemotherapy regimen BEAM (carmus-
tine, etoposide, cytarabine and melphalan) with antithymocyte glob-
ulin (ATG) 20mg/kg for 2 doses. Her transplant course was
complicated by septicaemia with Strep species. Six months after
the ASCT she recovered completely from the procedure and a prog-
ressMRI scan in April 2011 showed significant reduction of the CNS
inflammation and MS lesions. Furthermore she reported significant
improvement in mobility and bladder function.
Conclusions: The use of autologous BMT can be considered as an
option for patients with relapsing-remitting MS who have pro-
gressed on different immunotherapies. Careful selection of patients
with good performance status is crucial as this procedure carries
a 1% mortality risk.141
MULTI-DOSE PHARMACOKINETIC STUDY OF PLERIXAFOR IN A MOR-
BIDLY OBESE PATIENT WITH MULTIPLE MYELOMA AND DIALYSIS-DE-
PENDENT RENAL IMPAIRMENT
Vozniak, J.M.1, Davis, L.E.2, Stadtmauer, E.A.3 1Hospital of the Uni-
versity of Pennsylvania, Philadelphia, PA; 2College of Pharmacy, Univer-
sity of the Sciences, Philadelphia, PA; 3University of Pennsylvania,
Philadelphia, PA
Plerixafor is a CXCR4 antagonist approved formobilization of he-
matopoietic stem cells (HSC) in patients undergoing an autologous
stem cell transplant (AuSCT). Renal dose adjustments are recom-
mended but no data is available for dosing plerixafor in dialysis-de-
pendent patients. To our knowledge no literature describes the
pharmacokinetic (PK) characteristics of plerixafor in patients with
dialysis-dependent renal impairment.
We present a 44-year old morbidly obese (182kg; BMI 61.1) female
with IgGmultiplemyeloma with dialysis-dependent renal impairment
that underwent mobilization with plerixafor and filgrastim. Filgrastim
10mcg/kg/day was initiated 3 days before HSC collection 1. Prior to
plerixafor dosing the patient’s CD34+ 5 9 cells/microL. Plerixafor
started the evening of day 3 andHSCcollection 1 began 11 hours later.
Overall, 3 plerixafor doses were administered. HSC collection 2 began
16 hours after dose 2 and HSC collection 3 began 11 hours following
dose 3. Dialysis (HD) occurred after HSC collections 1 and 3.
Multi-dose PK analysis was conducted (WinNonlin). Data follow-
ing the first dose off HDwere fit to a 2-compartment model with Cl/
F: 3.56 L/hr, V/F: 56.6 L, distribution T1/2: 0.6 hr, and elimination
T1/2: 11 hr. The table summarizes non-compartmental analysis of
each parameter from each day.
Table. Plerixafor Pharmacokinetics by Dose
Apparent ApparentDose
NumberDose
(mg)Tmax
(hr)Cmax
(ng/mL)AUC 0-inf
(ng* hr/mL)Clearance
(L/hr)
Off HDClearance
(L/hr)
On HDHD (4 hr)
Schedule1 27 0.75 602 6406 3.57 10.7 Start 16.4 hr
post-dose2 27 1 665 10919 2.47 – –3 40 1 814 13463 2.16 8.0 Start 17.5 hr
post-doseinf 5 infinity; HD 5 dialysis
HSC collection 1, 2 and 3 yielded 2.2, 2.4 and 3.9 x 106 CD34+
cells/kg, respectively for a total of 8.5 x106 CD34+ cells/kg. Side-
Poster Session I S257effects included nausea, vomiting, diarrhea, dizziness and lighthead-
edness following doses 1 and 2. The patient underwent AuSCT and
achieved neutrophil engraftment on day +13 and platelet engraft-
ment on day +20.
Observations:Peak concentrations were proportional to dose. AUC
increased over the 3 days suggesting accumulation. Estimated clear-
ance on HD was 3-3.7 fold higher than clearance off HD. Cl/F and
V/F after dose 1 was comparable to published values while T1/2 is
longer. Maximum 40mg dose was effective and tolerated. Plerixafor
and filgrastim stimulated mobilization of HSC in the actively dia-
lyzed patient is feasible, well tolerated and results in adequate num-
bers of functional cells for use in AuSCT.142
LONG TERM ENGRAFTMENT IS ASSOCIATED WITH SURVIVAL AFTER AU-
TOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTI-
PLE MYELOMA
Bains, T., Lemieux, A., Abar, F., Maziarz, R.T., Chen, A.I. Knight Can-
cer Institute- Oregon Health and Science University, Portland, OR
The correlationwith long term engraftment on outcomes after au-
tologous transplantation is largely unknown. We conducted a retro-
spective analysis of 214 patients who underwent auto-SCT for
multiple myeloma from 1990 – 2009 and correlated long term en-
graftment of PBSC autografts (median CD34 dose 4.49; range
1.77-81.96) with outcomes. Patients who receivedmaintenance ther-
apy were not included in this analysis, and patients who relapsed
prior to assessment of engraftment were also excluded. Optimal en-
graftment was defined by NCI CTCAE grade 1 criteria for cytope-
nias (ANC$ 1,500/mm3, platelets$ 75,000/mm3, and hemoglobin
$ 10g/dL). The median age was 57 (range 31-76), and the median
follow-up was 2.9 years. At day 100, 40% of patients achieved opti-
mal engraftment, and 34% of patients had maintained these optimal
engraftment levels at 1 year. There were no significant differences in
gender, age, number of prior therapies, myelotoxic therapies (mel-
phalan, lenalidomide, or radiation), andCD34 dose between patients
with optimal vs sub-optimal engraftment. Cytogenetics and ISS
stage from diagnosis were not available in the majority of patients.
Performance status (KPS\90%) was associated with poor engraft-
ment at day 100 but not 1 year.
Engraftment at day 100 was not associated with outcome. How-
ever, patients with optimal engraftment at 1 year were observed to
have improved 3 year overall survival (89% vs 69%, p 5 0.05) but
not progression free survival (61% vs 62%). In our series, the major-
ity of patients did not achieve optimal long term engraftment after
auto-SCT in myeloma, and there appears to be a correlation of im-
paired long term engraftment with a deleterious effect on overall sur-
vival. Further analysis in larger data sets and other hematologic
malignancies to confirm this finding and to identify factors predictive
of long term engraftment is ongoing.143
PHASE IIA, OPEN-LABEL, RANDOMIZED, PHARMACOKINETIC COMPARA-
TIVE, CROSS-OVER STUDY OF MELPHALAN HCL FOR INJECTION (PRO-
PYLENE GLYCOL-FREE) AND ALKERAN FOR INJECTION FOR
MYELOABLATIVE CONDITIONING IN MULTIPLE MYELOMA PATIENTS
UNDERGOING AUTOLOGOUS TRANSPLANTATION
Aljitawi, O.S.1,2, Ganguly, S.1,2, Abhyankar, S.1,2, Wolfe, K.2,
Daniels, K.2, Ferree, M.3, Marks, R.3, Kramer, W.4, Pipkins, J.D.5,
McGruirk, J.P.1,2 1University of Kansas Medical Center; 2University of
Kansas Cancer Center; 3Clinipace Worldwide; 4Kramer Consulting
LLC; 5CyDex Pharmaceuticals, Inc. (A Ligand Company)
Background: Though high-dose melphalan and autologous trans-
plantation is a standard procedure in transplant eligible multiple my-
eloma patients. Themarketed formulation of melphalan, Alkeran for
Injection (Alkeran), has marginal solubility and limited chemical sta-
bility upon reconstitution. Alkeran uses propylene glycol as a co-sol-
vent, which has been reported to cause complications including renal
dysfunction and arrhythmias. Propylene Glycol-Free MelphalanHCL for Injection (PG-free Melphalan) is a reformulation of Al-
keran. It incorporates Captisol, a specially modified cyclodextrin,
to replace the co-solvents and improve stability. This abstract sum-
marizes the ultimate findings from this study after enrollment of all
planned patients.
Methods: This is a phase IIa, open-label, randomized, cross-over
design bioequivalence study. In this study, both the compartmental
and non-compartmental pharmacokinetics (PK) of PG-freeMelpha-
lan and Alkeran were assessed in the same MM patients undergoing
transplantation. Patients received both drug products in alternating
dosing day fashion and were their own control for PK comparison.
Furthermore, the safety and tolerability of high-dose melphalan
HCL and rates of myeloablation and subsequent engraftment were
determined in all patients.
Results: 24 patients, 11 females and 13males, were enrolled between
2/4/2010 and 05/16/2011 at TheUniversity of KansasMedical Cen-
ter and Cancer Center. All patients achieved myeloablation followed
by successful engraftment. Median time to myeloablation was 6 days
post the start of preparative regimen (range 3-8 days). Median time
to neutrophil engraftment was day +9.5 post transplant (range: 9-
12). No additional toxicities were reported with PG-freeMelphalan.
The following events occurred more frequently ($2 difference)
when Alkeran was given first (edema, headache, dysguesia, rash, bun-
dle branch block,) and the following events occurredmore frequently
($2 difference) when PG-free Melphalan was given first (dizziness).
PK analysis showed PG-free Melphalan was bioequivalent with Al-
keran and also revealed that Cmax and AUC were somewhat higher
after PG-free Melphalan.
Conclusions: PG-free Melphalan resulted in successful myeloabla-
tion and subsequent engraftment with no immediate infusion-re-
lated toxicity and no additional overall transplant-related toxicity.
PG-free Melphalan was bioequivalent to Alkeran while also demon-
strating a marginally higher systemic drug exposure.144
AN INNOVATIVE APPROACH TO AUTOLOGOUS STEM CELL COLLECTION
IN THE PEDIATRIC PATIENT
Peltz, A.C., Law, D.E., Giller, R.H. Children’s Hospital Colorado,
Aurora, CO
Autologous stemcell collection in the pediatric patient can be a chal-
lenging and expensive endeavor. Our institution has created a novel,
systematic procedure that has created a safe and efficient collection.
Using outpatient Interventional Radiology, we place two turbo flow
PICC lines with imaging –guided percutaneous technique centrally
in patients that are greater than 30 kg. In patients under 30 kg, we
are able to use double lumen broviacs or a single turbo flow PICC
and the existing central line (I.e. single lumen mediport or broviac).
Collection then takes place in our outpatient Apheresis Center without
sedation of the patient. We have successfully collected more than 54
pediatric patients, with differing diagnoses, using these methods since
the end of September 2008. We have had no documented line infec-
tions of the temporary PICC lines. This method allows for the pediat-
ric patient to remain an outpatient, with a low morbidity procedure,
but optimizing the stem cell collection process.CLINICAL CELLULAR THERAPY145
THE USE OF BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS
FOR TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS AND NEU-
RODEGENERATIVE DISORDERS – ACHIEVEMENTS AND FUTURE GOALS
Slavin, S., Brodie, C. International Center for Cell Therapy & Cancer Im-
munotherapy (CTCI), Tel Aviv, Israel; Bar-Ilan University, Ramat-Gan,
Israel
Future treatment of multiple sclerosis (MS) aims at restoringmye-
lination and neurological functions as well as re-induction of self-tol-
erance. We studied the role of mesenchymal stromal stem cells
(MSC), known to be anti-inflammatory on the one hand and
